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Abstract
Introduction In the search for novel cancer biomarkers,
various proteolytically derived peptides have been proposed
to exhibit cancer or cancer-type specificity. As these
peptides are presumably also generated after sample
collection by tumor-specific proteases, extensive investiga-
tion of the involved proteolytic processes is crucial for
further research.
Materials and Methods Using two previously developed
and fully validated liquid-chromatography coupled to
tandem-mass spectrometry assays, absolute quantification
of, in total, 13 proteolytically derived peptides in human
serum was accomplished. The analytes included eight
peptides derived from inter-α-trypsin inhibitor heavy
chain-4 (ITIH4-30, ITIH4-29, ITIH4-28, ITIH4-27, ITIH4-
26, ITIH4-25, ITIH4-22, and ITIH4-21), bradykinin, des-
Arg
9-bradykinin, Hyp
3-bradykinin, and fragments from
fibrinogen-α-chain (Fib-α [605–629]) and complement com-
ponent 4a (C4a [1337–1350]). Samples were obtained from
different healthy individuals and prepared with variable
tube types, clotting times, and temperatures. Furthermore,
stabilities in the serum fraction were assessed and compared
to stabilities in serum from breast cancer patients.
Results and Discussion The quantitative analyses showed
either increasing or decreasing serum concentrations during
blood coagulation, while comparable effects were observed
in serum separated from the blood clot. Furthermore,
comparisons of inter- and intra-individual variations sug-
gested better reflection of an individual’s protease activity
after prolonged ex vivo incubation. This was illustrated for
the putative breast cancer marker ITIH4-22, revealing better
differentiation after incubation of serum at ambient tem-
perature for 24 h.
Conclusion The presented study provides suggestions for
more specific and optimized sample preparation, as well as
extended knowledge necessary to further explore the
opportunities of these proteolytic peptides as cancer
biomarkers.
Keywords Biomarker.Cancer.Protease activity.LC-MS/
MS.Peptide.Sample handling
Introduction
Mass spectrometry-based profiling of the serum proteome
is a well-known approach in the search for biomarker
proteins able to predict specific cancer types in an early
stage [1, 2]. As a result, also the low molecular weight
serum proteome, or peptidome, has attracted increasing
attention [3–5], and this has resulted in the proposal of
various peptides with putative diagnostic characteristics for
different types of cancer in the past years [6–11]. In
addition to the classical principle that altered protein levels
are directly caused by the cancer type, the upregulated or
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cancer-specific interferences with protein or peptide break-
down pathways [3, 5]. Moreover, tumor-specific proteases,
including endo- and exopeptidases, have been postulated to
contribute to different serum peptidome profiles, also
suggesting ex vivo generation of candidate discriminatory
peptides after blood collection [10, 12, 13].
This hypothesis has received much criticism. On the one
hand, because it is likely to be highly subjected to
uncontrollable variables during sample collection, and on
the other hand, because of the questionability of the tumor’s
influence on the ex vivo peptide generation. As this process
depends on the activity of coagulation and complement
cascades, influences of other factors such as coagulation
disturbances or infections are suggested [14–16].
The contribution of various non-cancer-related factors to
serum peptidome profiles is widely accepted as a major
source of bias and one generally agrees on strict adherence
to completely standardized procedures [17–19]. Several
studies on the influence of pre-analytical factors on the
serum peptidome profile have been performed to further
optimize the standardized protocols. Especially the type of
blood collection tube, variations in clotting time and
temperature, storage conditions, and amount of freeze-
thaw cycles have been investigated and shown to have
significant effects on the serum peptidome profile [18–24].
For example, effects of clotting time have been categorized
by Umemura et al. [25] as types A, B, or C, in which types
A and B indicate decreasing and increasing serum concen-
trations, respectively, with increased clotting time. Type C
is defined as showing an initial increase, while remaining
relatively stable thereafter.
However, the abovementioned studies on sample han-
dling effects were not quantitative and based on general
observations of spectral changes, not providing any specific
information on particular peptides. Therefore, to better
understand the effects of sample handling variables on the
specific expression in serum of putative peptidome markers
generated after blood collection, novel quantitative methods
will be beneficial.
Two methods using liquid chromatography coupled to
tandem mass spectrometry (LC-MS/MS) have previously
been developed in our laboratory for the absolute quanti-
fication of, in total, 13 putative biomarker peptides in
human serum. One method allows simultaneous quantifi-
cation of eight proteolytic cleavage products of inter-alpha
trypsin inhibitor heavy chain 4 (ITIH4-30, ITIH4-29, ITIH4-
28, ITIH4-27, ITIH4-26, ITIH4-25, ITIH4-22, and ITIH4-21;
corresponding with ITIH4 [658–687]–ITIH4 [667–687])[ 26, 27],
each associated with different types of cancer [7, 9–11].
The other method involves the quantification of bradykinin,
Hyp
3-bradykinin, des-Arg
9-bradykinin, and fragments of
fibrinogen α-chain (Fib-α [605–629]), inter-α-trypsin inhib-
itor heavy chain 4 (ITIH4[ 6 6 6 –687]), and complement
component 4a (C4a [1337–1350])[ 28]. These peptides were
all significantly increased in serum from breast cancer
patients in the study of Villanueva et al. [10], which could
be confirmed for des-Arg
9-bradykinin and ITIH4-22 after
analysis of a large set of clinical serum samples from breast
cancer patients and matched controls in our laboratory [29].
In addition, absolute quantification of the eight ITIH4-
derived peptides in a similar sample set revealed statisti-
cally significant up-regulation of ITIH4-29 in serum from
breast cancer patients [30]. The Fib-α fragment has
furthermore been proposed as a marker for HER2-positive
breast cancer in another study [8] and as a tumor marker for
oral cancer [6]. An overview of the investigated specific
proteolytic peptides and their respective amino acid
sequence are shown in Table 1.
Now, with the use of these quantitative methods, we
specifically investigated the effects of clotting time, the
blood collection tube, and clotting temperature on the
serum concentrations and stabilities of these peptides.
Furthermore, the effects of ex vivo protease activities in
serum were compared between several breast cancer
patients and controls. Expanded knowledge on the above-
mentioned effects is required to further explore the
biomarker potential of the different peptides for early-
cancer diagnosis. For example, little differences in sample
handling can be a possible explanation for the observed
differences between the study of Villanueva et al. [10] and
the recently reported quantitative results [29, 30]. The
specific investigations described here can help in optimiz-
ing sample handling protocols for each particular peptide,
ideally resulting in (1) the lowest possibility of confounding
factors to affect the serum peptide concentration; (2) the
highest expression of the peptide formed after proteolytic
cleavages; and (3) the most significant differentiation
between protease activities in serum from controls and
cancer patients.
Materials and Methods
Blood Collection and Serum Preparation
Blood was collected at three different locations. At Saltro
Diagnostic Center Utrecht (Utrecht, The Netherlands),
blood was collected from four healthy individuals in
micronized silica-coated plastic (polyethylene terephthalate;
PET) tubes from Greiner Bio-One (Alphen a/d Rijn, The
Netherlands), either with (4 ml #454071) or without (4 ml
#454314) an inert olefinoligomer barrier gel. From one of
these four individuals, additional blood samples were taken
at two other locations with time intervals of ca. 1 month
between each occasion of blood collection. In the Utrecht
116 Clin Proteom (2010) 6:115–127Medical Center (UMC, Utrecht, The Netherlands), plastic
(PET) silicone-coated tubes with clot activator (micronized
silica particles) and a polymer gel separator from Becton
Dickinson (Breda, The Netherlands) were used (Vacutainer
3.5 ml SST tubes, #367057). At the third location, Sports
Medical CenterPapendal(SMCP,Arnhem, TheNetherlands),
blood was collected in the same plastic tubes with clot
activator andgel separator asusedatSaltro (GreinerBio-One;
4 ml #454071).
In all cases, blood of each volunteer was collected in seven
tubes that contained clot activator and gel separator and were
thereafter allowed to clot at room temperature (RT) for 0.5, 1,
2, 4, 6, 8, or 24 h. From the four individuals, one additional
tube with gel separator was allowed to clot for 24 h at 5°C,
while the two plastic tubes without gel separator were kept
either at RT for 1 h or at 5°C for 24 h.
After the specified clotting time, all samples were
centrifuged at 1,500×g for 10 min at 23°C. Subsequently,
three 100-μl aliquots of serum were taken, while the
remaining serum was divided into 500-μl portions. All
aliquots were immediately stored at −80°C after preparation.
Sample Preparation
All samples were thawed and further processed on ice.
Aliquots of 500 and 100 μl were purified by solid-phase
extraction on mixed-mode weak cation exchange [28]o r
silica C2 reversed-phase sorbents [27], respectively.
For assessing the stabilities in serum, 100 μl aliquots
from the sample with the shortest clotting time (30 min)
were left at RT for 0.5, 1.5, 3.5, 5.5, 7.5, and 23.5 h. This
was also performed with 500-μl aliquots of the blood
collected at the SMCP from one individual. Furthermore,
for all individuals, additional serum aliquots were left at RT
for 4 h, using two serum samples from both tube types,
with clotting procedures of either 1 h at RT or 24 h at 5°C.
LC-ESI-MS/MS Analysis
The LC-MS/MS analyses were performed as described in
detail previously [27, 28]. Both assays were performed
using an Accela high-speed chromatographic system
coupled to a TSQ Quantum Ultra triple quadrupole mass
spectrometer equipped with a heated electrospray ionization
source (all from Thermo Fischer Scientific, San Jose, CA,
USA), using multiple reaction monitoring for detection.
For both procedures, calibration standards and quality
control (QC) samples were prepared in analyte-free bovine
plasma, using stable-isotope labeled peptides or structural
analogs as internal standards. Accuracies and precisions of
the QC samples were determined to monitor analytical
performance, and the quantitative analysis was accepted
when deviations from the expected concentrations and
variations were below 15%.
Protease Activities in Serum from Breast Cancer Patients
Serum aliquots of 500 μl from nine breast cancer patients,
as well as from nine controls were incubated at RT for 24 h,
subsequently analyzed by LC-MS/MS to quantify serum
levels of the six putative breast cancer marker peptides.
Furthermore, 100 μl aliquots from 13 different patients and
controls were prepared in duplicate to obtain absolute
serum concentrations of the eight ITIH4-derived peptides:
one aliquot was directly further processed, while the other
sample was left at RT for 24 h before further processing.
All serum samples were obtained uniformly following a
strict standardized protocol at two different locations: the
Slotervaart Hospital and the Netherlands Cancer Institute/
Antoni van Leeuwenhoek Hospital (both in Amsterdam,
The Netherlands) after approval by the local medical ethics
committees of both hospitals, and after receiving individ-
uals’ written informed consent. The serum samples from
Name Fragment
a Amino acid sequence
Fib-α [605–629] Fib-α [605–629] DEAGSEADHEGTHSTKRGHAKSRPV
C4a [1337–1350] C4a [1337–1350] NGFKSHALQLNNRQ
Bradykinin HMWK [381–389] RPPGFSPFR
Hyp
3-Bradykinin HMWK
b
[381–389] RPP°GFSPFR
b
Des-Arg
9-bradykinin Bradykinin [1–8] RPPGFSPF
ITIH4-21 ITIH4 [667–687] SRQLGLPGPPDVPDHAAYHPF
ITIH4-22 ITIH4 [666–687] SSRQLGLPGPPDVPDHAAYHPF
ITIH4-25 ITIH4 [663–687] GVLSSRQLGLPGPPDVPDHAAYHPF
ITIH4-26 ITIH4 [662–687] PGVLSSRQLGLPGPPDVPDHAAYHPF
ITIH4-27 ITIH4 [661–687] RPGVLSSRQLGLPGPPDVPDHAAYHPF
ITIH4-28 ITIH4 [660–687] FRPGVLSSRQLGLPGPPDVPDHAAYHPF
ITIH4-29 ITIH4 [659–687] NFRPGVLSSRQLGLPGPPDVPDHAAYHPF
ITIH4-30 ITIH4 [658–687] MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF
Table 1 Amino acid sequences
of the investigated proteolytic
peptides
aAmino acid sequence of precur-
sor proteins derived from NCBI
protein database [35]
bContains a hydroxylated proline
amino acid residue, indicated by °
Fib-α Fibrinogen-α chain;
C4a complement component
4a; HMWK high molecular
weight kininogen; ITIH4 inter-α-
trypsin inhibitor heavy chain 4
Clin Proteom (2010) 6:115–127 117the breast cancer patients were obtained prior to surgery,
and none of them was undergoing treatment. Most breast
cancer patients were postmenopausal except for five
premenopausal and two menopausal women. The serum
samples from the controls (median age 56.1 years; inter-
quartile range (IQR) 46.4–69.5 years) were matched to the
serum samples from the breast cancer patients for age
(median age 56.2 years; IQR 44.7–69.9 years) and storage
duration (median 41 months for both groups).
Bloodwascollectedin9.5mlBDVacutainer®SST™tubes
(Beckton-Dickinson) and allowed to clot for exactly 30 min at
RT,afterwhichtheywerecentrifugedat1,500×g for 15 min at
RT and subsequently aliquoted and stored at −80°C.
Results and Discussion
Effect of Clotting Time
The effects of the clotting time on the serum concentrations
of Fib-α [605–629], C4a [1337–1350], bradykinin, and des-Arg
9-
bradykinin from healthy individuals are shown in Fig. 1.
The Fib-α [605–629] fragment showed increasing concen-
trations with prolonged clotting time (Fig. 1a)i na l l
individuals. This type B-effect [25] can for Fib-α [605–629]
be related to increased breakdown of fibrinogen and
fibrinogen-alpha chain during blood coagulation and
fibrinolysis [31].
The concentrations of C4a [1337–1350] were low in all
serum samples (max. 2.3 ng/ml) and below the lower limit
of quantification (LLOQ) for several samples (Fig. 1b).
Nevertheless, a small initial increase in the serum concen-
tration could be observed during the first 2 h of clotting,
thereafter slightly decreasing and this type of effect was
classified as type C [25]. This effect probably indicates a
reduced amount of the founder peptide, i.e., complement
component 4a, with C4a [1337–1350] as an intermediate in
further proteolytic processing. Besides the formation of
proteolytic cascades, blood clotting can stimulate comple-
ment activation, although the exact mechanism of this
interplay remains unclear [32]. On the other hand,
activation of the complement cascade by blood coagulation
can explain the initial increase in the proteolytic fragment
of C4a, which is thereafter susceptible to consecutive
proteolytic cleavages.
Bradykinin, des-Arg
9-bradykinin, and Hyp
3-bradykinin
showed rapid decreases with prolonged clotting time
(Fig. 1c, d), and maximum serum concentrations were
measured in the sample with the shortest clotting time (type
A[ 25]). However, for des-Arg
9-bradykinin, a C-type initial
increase during the first 30 min can be expected due to
proteolytic cleavage of bradykinin. Bradykinin is a key
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Fig. 1 Effects of clotting time at RT on serum concentrations of a Fib-α [605–629]; b C4a [1337–1350]; c bradykinin; and d des-Arg
9-bradykinin in
four healthy individuals (represented by different lines). The dotted line represents the assay’s LLOQ
118 Clin Proteom (2010) 6:115–127component in the intrinsic pathway of coagulation as the first
step is activation of kallikrein, a serine proteinase which
cleaves high molecular weight kininogen and releases
bradykinin [31, 33]. However, bradykinin is also known to
be rapidly degraded ex vivo, for example by carboxypepti-
dases N at the 8–9 position to yield des-Arg
9-bradykinin.
Both bradykinin and des-Arg
9-bradykinin are predominantly
cleaved by angiotensin I converting enzyme at the 7–8a n d
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Clin Proteom (2010) 6:115–127 1195–6 positions [34]. The type-A effect for both peptides
indicates that bradykinin is generated at the beginning of the
ex vivo intrinsic pathway [10] and then rapidly degraded to
mainly des-Arg
9-bradykinin which is thereafter highly
susceptible to further proteolytic cleavages.
Clotting time effects on the serum concentrations of the
ITIH4-derived peptides are shown in Fig. 2, revealing
increasing serum concentrations upon increased clotting
time (type B [25]). Only for ITIH4-27 and ITIH4-30
(Fig. 2e, h), decreasing serum concentrations were observed
after ±4–6 h clotting at RT. The effect of clotting time on
ITIH4-27 and ITIH4-30 was, therefore, categorized as type
C[ 25], simply defined in this study as initially increasing,
while thereafter decreasing within 6 h after blood collec-
tion. ITIH4 is known to be very sensitive to cleavage by
plasma kallikrein [35], followed by trypsin-like cleavages
and subsequent terminal truncations by common plasma
proteases [36]. The carboxy termini of the ITIH4 fragments
measured in this study are identical and consistent with a
previously reported cleavage site [37]. The effects of
prolonged clotting times on the serum concentrations of
these peptide fragments indicate that the peptides are
mainly generated ex vivo, with ITIH4-27 and ITIH4-30 as
most sensitive to subsequent proteolysis. This is in
agreement with previously observed highest susceptibility
to degradation of synthetic ITIH4-27 in plasma and serum,
thereby apparently generating ITIH4-25 [26].
Although these results show that blood coagulation
affects the serum concentrations of all peptides, they cannot
be solely attributed to the clotting process. Thorough
investigation of the specific role of the involved proteases
and the founder peptides as well as their relation with blood
coagulation and fibrinolysis is, therefore, required. For
example, it remains unclear whether the different extent of
the observed effects between the four individuals is caused
by the presence of different proteases or by differences in
activities of the same combination of proteolytic enzymes.
On the other hand, these results indicate the relevance of
adherence to strict standardized protocols as the ongoing
proteolytic breakdown in blood during the clotting process
easily introduces pre-analytical variance. Furthermore, the
protease activities can have completely opposite effects on
the various peptides, apparently necessitating different
blood collection procedures for the different peptide types.
For example, adequate quantification of the ITIH4 peptide
fragments in clinical serum samples, with clotting times of
exactly 30 min, was seriously complicated by the low
expression of these peptides [26, 29]. Prolonged clotting
time of the blood samples could be beneficial for more
accurate analytical measurements. Contrary, analysis of
bradykinin and Hyp
3-bradykinin likely requires very short
clotting times, although their ex vivo degradation occurs so
rapidly that robust serum preparation will still be seriously
complicated. Interestingly, Yi et al. [24] suggest the
addition of protease inhibitors prior to blood collection to
reduce artificial generation of bradykinin by activation of
the kallikrein–kinin system by surface contact with blood
collection devices. Nevertheless, as long as the tumor’s
effect on the endo- and/or exoprotease activity, and thus
eventually on the bradykinin serum concentrations, is not
elucidated, the most appropriate sample preparation proce-
dures remain speculative.
Effect of Clotting Temperature
Serum concentrations for the various peptides were com-
pared after clotting of the blood for 24 h at either RT or 5°
C. Unfortunately, this clotting time was too long to present
any results for the rapidly degraded bradykinin and Hyp
3-
bradykinin. Results for the other peptides are presented in
Fig. 3, in which the average concentrations after clotting at
RT are expressed as% of the average concentrations
measured after clotting at 5°C. As can be seen in Fig. 3,
peptides which are most likely being degraded after 24 h
(type B/C) such as Des-Arg
9-bradykinin, C4a [1337–1350],
ITIH4-27, and ITIH4-30 show higher concentrations in the
tubes stored at lower temperature, whereas peptides which
are generated along with blood clotting (type A), generally
show higher concentrations in the tubes stored at higher
temperature. This is not surprising as the protease activities
Fig. 3 Effect of clotting temper-
ature on the serum concentrations
of the various peptides, expressed
as% average response after 24 h
clotting at RTcompared to 5°C.
Error bars indicate the standard
deviation (n=4)
120 Clin Proteom (2010) 6:115–127are likely to be lower at lower temperatures. The only
exception is ITIH4-26, still showing increasing concen-
trations after 24 h clotting at RT, but with higher
concentrations when clotting occurred at 5°C. This once
more suggests interference of various specific proteases,
either degrading or generating ITIH4-26, with the degrading
proteases more specifically inhibited by the lower temper-
atures. Similarly, ITIH4-29 concentrations appeared more or
less unaffected by the clotting temperature, while some of
the type-C peptides showed remarkable high concentrations
when clotting occurred at 5°C (e.g., 4.1±1.8 ng/ml for C4a
[1337–1350] and >10 times the upper limit of quantification
for ITIH4-30). This agrees with the suggestion that
proteolysis of these peptides is apparently more reduced at
lower temperatures than the degradation of their respective
founder peptides. Moreover, the mentioned peptides, C4a
[1337–1350], ITIH4-26 and ITIH4-30, are all preceded by an
arginine amino acid residue at their N terminus [38],
indicating involvement of the same (trypsin-like) enzyme
that is not inhibited by the reduced temperature.
With the observed influence of clotting temperature on
the final serum concentrations, careful control and registra-
tion of the clotting temperature are required. Additionally,
clotting at lowered temperatures can be beneficial to
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Clin Proteom (2010) 6:115–127 121minimize the effects of small variations in clotting time
and/or to provide higher and more accurately measurable
concentrations for specific peptides as observed for C4a
[1337–1350] and likely expected for bradykinin peptides.
Effect of Collection Tube
Two types of silica-coated plastic serum collection tubes
were compared. Besides the silica to activate the coagula-
tion process, one tube contained a separation gel in the base
of the tube, forming a barrier between serum and blood
cells after centrifugation. Figure 4 shows the measured
concentrations of the different peptides in serum from four
healthy individuals (♦, ■, ▲, and X) after 1 h clotting at RT
in the different tube types (when concentrations were too
low after 1 h clotting, shown results were obtained after
24 h clotting at 5°C). Besides the effect of the serum
collection tube on the measured serum concentration of the
different peptides, the separate presentation of the four
healthy individuals provides additional insight in the
complex formation and degradation processes of the
proteolytic peptides.
For most peptides, serum concentrations were higher if
prepared in tubes with gel separator (Fig. 4). Only for A-
type peptides, with observed ex vivo degradation, lower
concentrations were measured, suggesting increased prote-
ase activity by the gel. However, C4a [1337–1350], des-Arg
9-
bradykinin, ITIH4-21, and ITIH4-28 showed some contrast-
ing results for at least one individual. For C4a [1337–1350],
this could possibly be attributed to the absence of the gel
barrier between serum and blood clot after centrifugation in
one of the tubes (▲). Des-Arg
9-bradykinin on the other
hand showed contrasting effects for the samples with a low
concentration in the tubes with gel, compared to the
samples with a clearly higher concentration, due to higher
bradykinin concentrations in these individuals (Fig. 1).
Therefore, reduced breakdown of bradykinin in the tubes
without gel results in lower concentrations of des-Arg
9-
bradykinin for these individuals compared to the concen-
trations obtained in tubes with gel separator. In agreement,
des-Arg
9-bradykinin concentrations after 24 h clotting (not
shown) were higher in serum from tubes without gel for all
individuals due to the absence of bradykinin and reduced
proteolysis of des-Arg
9-bradykinin in this tube type. The
results for Hyp
3-bradykinin showed the same pattern as for
bradykinin, although lower concentrations were measured
(not shown).
Nevertheless,observeddeviationsforsomepeptidesinone
or more healthy individuals suggest possible interference of
the gel with peptide’s formation, introducing unexplained
inter-individual variations. For example, ITIH4-21 showed an
opposite (increased) effect for one individual (x) in the tube
without gel. Interestingly, for the same individual (x) the
increase in ITIH4-21 concentration with prolonged clotting
time at RT was less pronounced compared to the other
individuals (Fig. 2a), while the increase in serum left at RT
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Fig. 5 Comparison between effects of incubation time at RT in serum
during blood clotting (straight line) and serum after rapid removal of
the blood clot (dotted line) on the absolute serum concentrations of a
ITIH4-21 and b ITIH4-25 in four healthy individuals (diamonds,
squares, triangles, and ex symbols)
122 Clin Proteom (2010) 6:115–127for similar periods of time was remarkably higher for this
individual (Fig. 5a). However, as discussed before, the exact
mechanism behind the observed different effects between the
four individuals remains unclear.
Stability in Serum
Similar as during the clotting process, continuing protease
activities caused alterations in the serum concentrations
when serum was left at RT after removal of the blood clot.
The ITIH4-derived peptides were measured in serum from
which the solid material was removed after clotting for
30 min and which was subsequently incubated at RT for
different periods of time. All peptides showed similar
patterns, concerning the changes in serum concentrations,
compared to the effect of incubation at RT in the presence
of the blood clot, as presented in Figs. 1 and 2. Moreover,
for some individuals, identical concentrations were mea-
sured in serum left at RT for the same period of time either
during or after clotting. Examples of the measured concen-
trations in serum from healthy individuals with similar
incubation times at RT with or without the presence of the
solid clot material are shown for ITIH4-21 and ITIH4-25 in
Fig. 5.
For Fib-α [605–629], C4a [1337–1350], bradykinin, Hyp
3-
bradykinin, and Des-Arg
9-bradykinin similar comparisons
were performed for only one healthy individual as their
quantification required a larger serum volume (500 μl).
Nevertheless, an indication of the ex vivo stabilities of
these peptides in the serum fraction was provided by
comparing serum concentrations after incubation at RT for
4 h to directly analyzed serum concentrations. These
measurements showed that Fib-α [605–629] was less obvi-
ously generated in serum after removal of the blood clot as
during blood clotting, as shown for one individual in Fig. 6.
This is not surprising as Fib-α [605–629] is a degradation
product of the alpha chain of fibrinogen and is probably
generated by plasmin cleavages during the fibrinolysis
process in the remaining blood clot [31].
For the other peptides, similar changes in serum
concentrations were generally observed for all healthy
individuals in the different serum samples after 4 h
incubation at RT as compared to the effects in the presence
of the blood clot (Table 2). Nonetheless, Fib-α [605–629] and
ITIH4-30 concentrations were lower after 4 h incubation at
RT in serum preceded by 24 h clotting at 5°C (except for
Fib-α [605–629] from tubes with separator gel), in contrast to
their increased concentrations in serum preceded by 1 h
clotting (Table 2). Apparently, observed effects merely
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Fig. 6 Comparison between effects of incubation time at RT in serum
during blood clotting (straight line) and serum after rapid removal of
the blood clot (dotted line) on the absolute serum concentrations of
Fib-α [605–629] in one healthy individual
Peptide Relative difference (%) ±standard deviation
Serum preparation Clotting time (h); temperature (°C) Tube with gel Tube without gel
Fib-α [605–629] 1; RT + 48.3±30 + 7.4±8
Fib-α [605–629] 24; 5 +18.9±8 −19.0 ±12
C4a [1337–1350] 24; 5 −54.5±17 −55.5±18
Bradykinin 1; RT −64.3±18 −53.9±23
Des-Arg
9-bradykinin 24; 5 −82.9±3 −87.1±5
ITIH4-21 24; 5 + 151.6±20 + 298.1±124
ITIH4-22 24; 5 + 95.3±40 + 75.4±17
ITIH4-25 24; 5 + 417.5±99 + 361.7±108
ITIH4-26 24; 5 + 35.2±13 + 30.0±11
ITIH4-27 24; 5 + 202.5±43 +139.0±52
ITIH4-28 24; 5 + 90.4±12 + 127.7±42
ITIH4-29 24; 5 + 109.4±46 + 71.9±10
ITIH4-30 1; RT + 33.1±23 + 18.8±14
ITIH4-30 24; 5 −10.9±12 −11.7±20
Table 2 Averagerelativechanges
in serum concentrations after
incubation of serum from four
healthy individuals for 4 h at RT
Clin Proteom (2010) 6:115–127 123depend on the amount of the generated, or yet degraded,
founder peptides during coagulation than on different
protease activities in serum compared to blood during
coagulation. Most interesting is the observation of com-
pletely identical ex vivo effects in either blood or serum on
the concentrations of several peptides in some individuals
(Fig. 5). This indicates that for these peptides protease
activities are not solely depending on blood coagulation,
which is a major argument in questioning putative tumor
specificity in ex vivo peptide generation.
Intra- vs. Inter-Individual Variations
As partly discussed above and illustrated in Figs. 1, 2, 3, 4,
and 5, large variations in the serum concentrations of the
peptides were already observed between four healthy
individuals. Lowest inter-individual relative standard devi-
ations (RSD) in samples with the shortest clotting time
were observed for Fib-α [605–629] and ITIH4-29 (10.8% and
14.1%, respectively), while variations were particularly
high for bradykinin, des-Arg
9-bradykinin, and ITIH4-28
(138, 57% and 44% RSD, respectively). Additionally,
effects of clotting time on the serum concentrations of the
various peptides were compared for one individual from
whom blood was collected on three different days.
Examples of intra-individual variations in C4a [1337–1350],
des-Arg
9-bradykinin, ITIH4-22, and ITIH4-27 serum con-
centrations are presented in Fig. 8.
Interestingly, intra-individual variations were obviously
much lower after 24 h clotting as compared to the inter-
individual variations for most peptides, especially for the
ITIH4-derived peptides (varying from 1.4% RSD for ITIH4-
22 to 15.0% RSD for ITIH4-28). This is clearly indicated
for ITIH4-22, showing similar high concentrations after
24 h clotting in one individual (Fig. 7), although ITIH4-22
concentrations were obviously much lower in the other
individuals after prolonged clotting (Fig. 2).
These results suggest that prolonged incubation, allow-
ing further proteolytic breakdown, likely increases inter-
individual variabilities, while reducing intra-individual
variations, although observed for only one individual at
three different moments. Eventually, prolonged ex vivo
processing possibly reduces the effect of confounding
factors, providing a better reflection of one individual’s
endo- and/or exoprotease activity as well as a better
differentiation between protease activities in different
individuals. However, it is difficult to say whether these
variations are wanted (expressing variations in the activity
of proteases of interest) or unwanted (caused by factors
other than disease-related activities of proteases, e.g.,
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Fig. 7 Examples of intra-individual variations (diamonds) in clotting
time effects at RT on the serum concentrations of a C4a [1337–1350], b
Des-Arg
9-bradykinin, c ITIH4-22 and d ITIH4-27 in samples collected
on three different days at Saltro (dark-gray), UMC (light-gray)o r
SMCP (black). The dotted line represents the assay’s LLOQ
124 Clin Proteom (2010) 6:115–127coagulation status). Nonetheless, if variations between the
four healthy individuals are only caused by haemostatic
differences, one would expect similar inter-individual
variations for all peptides. This is clearly not the case, e.
g., the individual that showed much higher concentrations
of ITIH4-22 after prolonged clotting (Fig. 2) than the other
individuals, showed more or less similar protease depen-
dent formation of the other ITIH4 fragments. This suggests
interferences of more specific proteases than those solely
depending on the coagulation and complement activation.
Moreover, the complicated history of the studied
peptides is likely to contribute to the observed variations
as their formation depends on (1) generation of founder
peptides by ex vivo proteolysis, eventually activated during
clotting, (2) cleavage of these founder peptides by exo- and
or endoproteases, and (3) simultaneous breakdown of the
peptide itself.
Comparison Between Breast Cancer Patients and Healthy
Controls
Measured minimum, maximum, and median concentrations
of the 13 peptides after direct measurement or 24 h
incubation at RT are presented in Table 3. These measure-
ments were especially intended to investigate the effects of
prolonged ex vivo exposure to protease activities on the
eventual discriminatory properties of the different peptides
in breast cancer. The comparison of absolute serum
concentrations to investigate the actual discriminatory
properties of ITIH4-22, Fib-α [605–629], C4a [1337–1350],
bradykinin, and des-Arg
9-bradykinin has been described
Table 3 Measured concentrations of the various peptides in serum from breast cancer (BC) patients and controls (CO) after direct measurement
or after 24 h incubation at RT
Direct measurement After 24 h at RT
Median concentration [Range]
a (ng/ml) P value
c Median concentration [Range]
a (ng/ml) P value
c
Peptide n BC CO BC CO
Fib-α [605–629] 9 157.9 [81–238] 186.6 [85–493] .402 336.4 [112–423] 319.4 [180–571] .453
C4a [1337–1350] 9 1.7 [0.5–5] 2.2 [0.5–8] .251 1.7 [1–2] 1.3 [0.5–3] .566
Bradykinin
d 9 94.2 [38–165] 76.3 [57–140] .566 35.1 [8–102] 38.4 [26–98] .566
Des-Arg
9-bradykinin 9 97.6 [69–152] 87.3 [46–168] .402 66.3 [13–120] 78.9 [59–114] .453
ITIH4-21 13 6.2[1–54] 3.1 [1–11] .118 40.1 [4–139] 33.0 [1–84] .555
ITIH4-22 22 1.1
b [1–18] 0.5
b [1–5] .135 6.3 [1–53] 4.0 [1–13] .046
ITIH4-25 13 2.7 [1–22] 1.4 [1–2] .061 28.3 [6–358] 20.8 [4–74] .033
ITIH4-26 13 6.3 [2–672] 4.0 [1–8] .077 14.3 [2–605] 8.7 [3–44] .144
ITIH4-27 13 1.7 [1–22] 1.0 [1–4] .274 5.0 [1–43] 2.8 [1–16] .077
ITIH4-28 13 4.2 [2–50] 2.4 [1–7] .061 31.2[4–82] 23.6 [1–44] .522
ITIH4-29 13 5.2 [1–101] 2.7[1–6] .043 25.9 [4–306] 13.7 [1–58] .043
ITIH4-30 13 37.2 [5–4078] 19.0 [3–58] .038 33.6 [5–279] 20.7[6–94] .038
aMeasurements below the LLOQ are set at 1/2 LLOQ; measurements above the ULQ are presented as the extrapolated value
bQuantified with two methods (13 samples together with the ITIH4-derived peptides and nine with the putative breast cancer markers). All values below
1 ng/ml were set at 0.5 ng/ml
cUsing Mann–Whitney U test. Values in bold indicate P values <.05
dResults for bradykinin were similar as for bradykinin, though at lower concentrations and are not presented
Direct measurement After 24 h incubation
Fig. 8 Box plots indicating the median ±25th percentile (IQR) for
ITIH4-22 in serum from breast cancer patients (BC, n=22) and
controls (CO, n=22) after direct measurement, as well as after
incubation of the serum for 24 h at RT. The lower and upper bars
indicate the lowest and highest value within 1.5 IQR, respectively,
while dots represent values between 1.5-3 IQR (outliers) and asterisks
values above 3 IQR (extremes)
Clin Proteom (2010) 6:115–127 125earlier in a larger population (n=62) [29]. That measure-
ment revealed that from these peptides, which were all
proposed by Villanueva et al. [10] to exhibit putative
discriminative properties for breast cancer, only ITIH4-22
and des-Arg
9-bradykinin showed significantly up-regulated
serum concentrations in breast cancer patients [29]. In
addition, a similar comparison of absolute serum concen-
trations of the eight ITIH4-derived peptides recently
revealed significant upregulation of particularly ITIH4-29
[30].
Here, comparison of the measured concentrations after
direct measurement between the control and breast cancer
group, using Mann Whitney U tests, showed statistically
significant differences (P<0.05) for ITIH4-29 and ITIH4-30
(Table 3). The differences for these peptides were still
significant after 24 h incubation of the serum at RT, while
with these conditions also ITIH4-22 and ITIH4-25 showed
significantly upregulated serum concentrations in breast
However, the sample size in this study was relatively small
and significances only marginal, complicating adequate
interpretation of the results. This study does not provide
evidence on the existence of differential ex vivo proteolytic
processing in breast cancer, which was investigated in more
detail in other studies [29, 30]. On the other hand, prolonged
exposure to ex vivo proteolysis appeared effective for
improved differentiation between breast cancer and controls
for ITIH4-22 and ITIH4-29, visualized in a box plot for
ITIH4-22 in Fig. 8. Furthermore, it should be noted that
when breast cancer-specific proteases simply have no
influence on the generation of these proteolytic peptides,
no significant effects after prolonged protease exposure can
be expected. For future investigations, prolonged exposure to
ex vivo proteolysis might, therefore, be seriously considered.
Conclusions
Owing to the recent development of two selective and
specific LC-MS/MS methods for the absolute quantification
of, in total, 13 proteolytic peptides in human serum, it was
possible to accurately determine the specific influence of
several sample handling variables on the serum concen-
trations of these putative cancer biomarkers. The results
presented in this manuscript show that clotting time,
temperature, and type of collection tube drastically affect
the final serum concentrations. The different impact of
these effects on the various peptides demonstrates the
necessity of more specific sample preparation procedures to
provide more consistent results and further investigate the
large number of proteolytic peptides proposed as putative
biomarkers for different types of cancer by various semi-
quantitative studies. This study, therefore, very well
provides suggestions for follow-up investigations to better
explore the potential of these peptides as possible bio-
markers.
Furthermore, similar ex vivo degradation and/or gener-
ation of the various peptides by proteases in serum as
during coagulation showed that the protease activities are
not solely depending on blood coagulation. This implies
that other factors than haemostatic conditions are very
likely to contribute to altered protease activities. Moreover,
the increased discriminative value of the potential breast
cancer marker ITIH4-22 after excessively long exposure to
ex vivo proteolysis could support the hypothesis of tumor
specific proteases and prolonged incubation of serum
samples therefore deserves consideration for future quanti-
tative comparisons of specific peptide fragments.
Ultimately, the presented study provides improved
awareness of the pitfalls and opportunities of the low
molecular weight peptidome in the search for novel cancer
biomarkers.
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